Based on these insights, we integrated IL-6 and EBV DNA levels to develop a prognostic risk stratification model for R/M NPC patients treated with chemoimmunotherapy, with the aim to predict patient prognosis and optimize therapeutic strategies in clinical practice. This evidence concerns the gene IL6 and nasopharyngeal carcinoma.